Why Most Biotech Companies Fail at Business Development (and How to Fix It)

Business development in life sciences requires a different playbook. Here is why standard sales tactics do not work, and what does.

Many biotech companies hire experienced business development leaders from other industries and watch them struggle. The technology is sound. The market is real. The BD professional is competent. Yet the results lag. The reason is rarely the people. It is the playbook. Business development in life sciences operates by rules that do not match generic B2B or SaaS frameworks. Founders who do not understand this difference often spend 12 to 18 months learning it the hard way. Below, three reasons standard BD fails in biotech, and the practices that actually generate commercial momentum.

Why generic BD does not work in biotech

Long sales cycles need long-term relationships: Biotech B2B sales cycles run 12 to 36 months. Cold outreach optimized for short sales cycles fails. By month nine, when the prospect is ready to buy, the relationship is gone. What works instead: relationship-building rhythms designed for long cycles. Scientific touchpoints, conference presence, published collaboration, peer introductions.


Buyers are scientists, not procurement officers: In biotech, the buyer is a scientist evaluating whether a technology solves a real problem. Generic sales pitches fail. What works instead: scientific credibility, published data, peer validation, and direct scientist-to-scientist conversations.


The decision is made before the demo: The buyer journey starts in spaces the company does not control. If your technology is invisible in early-stage discovery channels, you are competing for the runner-up position. What works instead: discoverability across scientific channels, search engines, and AI systems that biotech buyers increasingly use to research vendors.

When to engage a fractional BD partner

Many biotech companies face a familiar dilemma. They need senior commercial capacity but cannot justify a full-time hire.
A few signals that a fractional BD partner may be the right
answer:

  • Commercial activities are advancing too slowly relative to scientific milestones
  • The team has technical depth but limited commercial network
    in target markets
  • A full-time senior BD hire would consume more than 30 percent of available runway
  • Specific commercial gaps need addressing without long lead times

Fractional partnerships work when the partner brings sector expertise, established networks, and clear accountability.

How Auralis GROW supports companies

Auralis GROW supports biotech and diagnostics companies ready to generate traction and build commercial momentum.

Our work covers

  • Fractional BD partnership - senior commercial capacity embedded in your team, without the overhead of a full-time hire.
  • Partner and investor matchmaking - structured access to strategic partners, co-development counterparts, and investors across Europe.
  • Pharma/Biotech Intelligence and Authority Strategy - ensuring your platform is found by researchers, BD teams, and investors across search engines and AI-powered discovery systems.
  • Scientific content strategy - technical content built for commercial conversations: white papers, application notes, and investor-facing summaries.

Engagements are structured around your commercial stage and objectives. Start with a conversation.

Discuss your BD strategyTake the Free Market Readiness Audit